Option Care Health, Inc. $OPCH Shares Sold by Dimensional Fund Advisors LP

Key Points

• Dimensional Fund Advisors LP reduced its holdings in Option Care Health by 11.3%, owning 3,538,185 shares after selling 449,866 shares in the first quarter, which equates to approximately 2.16% of the company valued at $123.7 million.
• Option Care Health reported earnings per share of $0.41 for the latest quarter, exceeding analysts' estimates, and had revenues of $1.42 billion—up 15.4% year-over-year.
• Brokerages have set an average price target of $35.75 for OPCH shares, with multiple analysts rating the stock as a "Buy" or "Outperform."

Dimensional Fund Advisors LP trimmed its position in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 11.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,538,185 shares of the company's stock after selling 449,866 shares during the period. Dimensional Fund Advisors LP owned 2.16% of Option Care Health worth $123,655,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of OPCH. Northern Trust Corp boosted its holdings in shares of Option Care Health by 11.8% in the 4th quarter. Northern Trust Corp now owns 2,626,478 shares of the company's stock valued at $60,934,000 after acquiring an additional 278,158 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Option Care Health by 4.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,609,705 shares of the company's stock worth $91,209,000 after purchasing an additional 99,574 shares during the last quarter. Nuveen LLC acquired a new stake in Option Care Health during the 1st quarter worth $70,965,000. Allspring Global Investments Holdings LLC boosted its stake in Option Care Health by 6,525,926.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,500,986 shares of the company's stock worth $52,459,000 after purchasing an additional 1,500,963 shares during the last quarter. Finally, Comerica Bank boosted its position in shares of Option Care Health by 13.1% during the 4th quarter. Comerica Bank now owns 1,357,628 shares of the company's stock valued at $31,497,000 after acquiring an additional 157,198 shares during the last quarter. 98.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently weighed in on OPCH. Barrington Research reissued an "outperform" rating and set a $38.00 price target on shares of Option Care Health in a research report on Thursday, July 10th. JMP Securities boosted their target price on Option Care Health from $36.00 to $38.00 and gave the stock a "market outperform" rating in a research note on Thursday, July 31st. UBS Group upgraded shares of Option Care Health from a "neutral" rating to a "buy" rating and upped their target price for the stock from $38.00 to $40.00 in a research note on Wednesday, April 30th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Option Care Health in a report on Thursday, July 31st. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $35.75.

Insider Buying and Selling at Option Care Health

In other news, Director Harry M. Jansen Kraemer, Jr. purchased 36,000 shares of the company's stock in a transaction dated Wednesday, August 20th. The stock was acquired at an average price of $27.15 per share, for a total transaction of $977,400.00. Following the completion of the transaction, the director directly owned 375,390 shares in the company, valued at $10,191,838.50. This represents a 10.61% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Timothy P. Sullivan purchased 20,000 shares of the company's stock in a transaction dated Thursday, August 21st. The stock was purchased at an average price of $27.51 per share, with a total value of $550,200.00. Following the transaction, the director owned 49,229 shares of the company's stock, valued at approximately $1,354,289.79. This represents a 68.43% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.64% of the company's stock.

Option Care Health Stock Performance

Shares of NASDAQ OPCH traded up $0.90 during mid-day trading on Friday, hitting $28.74. 2,369,675 shares of the company were exchanged, compared to its average volume of 1,997,394. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.81. The stock has a 50 day simple moving average of $29.92 and a 200-day simple moving average of $31.75. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $35.53. The firm has a market cap of $4.66 billion, a price-to-earnings ratio of 19.96, a price-to-earnings-growth ratio of 1.75 and a beta of 0.79.

Option Care Health (NASDAQ:OPCH - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.01. The firm had revenue of $1.42 billion during the quarter, compared to analysts' expectations of $1.35 billion. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.Option Care Health's revenue was up 15.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.30 earnings per share. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. On average, sell-side analysts forecast that Option Care Health, Inc. will post 1.22 EPS for the current fiscal year.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.